JAB 30300
Alternative Names: JAB-30300; JAB-30355; P53 Y220C activator - Jacobio PharmaceuticalsLatest Information Update: 19 Jun 2024
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 19 Jun 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 01 Mar 2024 Jacobio Pharmaceuticals files an IND application with the US FDA in USA for Solid tumours prior to March 2024
- 01 Mar 2024 Jacobio Pharmaceuticals intends to file an IND application with the National Medical Products Administration (NMPA) in China for Solid tumours